Hyaluronidase activation of c-Jun N-terminal kinase is necessary for protection of L929 fibrosarcoma cells from staurosporine-mediated cell death

Biochemical and Biophysical Research Communications
N S Chang

Abstract

Hyaluronidase counteracts the growth inhibitory function of transforming growth factor beta (TGF-beta), whereas secretion of autocrine TGF-beta and hyaluronidase is necessary for progression and metastasis of various cancers. Whether hyaluronidase and TGF-beta1 induce resistance to staurosporine in L929 fibrosarcoma cells was investigated. When pretreated with TGF-beta1 for 1-2 h, L929 cells resisted staurosporine apoptosis. In contrast, without pretreatment, hyaluronidase protected L929 cells fromstaurosporine apoptosis. Hyaluronidase rapidly activated p42/44 MAPK (or ERK) in L929 cells and TGF-beta1 retarded the activation. Nonetheless, TGF-beta1 synergistically increased hyaluronidase-mediated inhibition of staurosporine apoptosis. Hyaluronidase rapidly activated c-Jun N-terminal kinase (JNK1 and JNK2) in L929 cells in 20 min. Dominant negative JNK1, JNK2, and JNK3 abolished the hyaluronidase inhibition of staurosporine apoptosis, but not the TGF-beta1 protective effect. Unlike the resistance to staurosporine, pretreatment of L929 cells with hyaluronidase is necessary to generate resistance to other anticancer drugs, including doxorubicin, daunorubicin, actinomycin D, and camptothecin, and the induced resistance was also blo...Continue Reading

References

Jan 1, 1992·Journal of Cancer Research and Clinical Oncology·K BeckenlehnerW Schiess
Mar 1, 1992·Kidney International·A B RobertsM B Sporn
Nov 6, 1991·Journal of the National Cancer Institute·M SternR Stern
Mar 13, 1986·Biochemical and Biophysical Research Communications·T TamaokiF Tomita
Aug 1, 1993·Immunology Today·P HerrlichH Ponta
Jan 1, 1995·Journal of Cancer Research and Clinical Oncology·T SprussW Schiess
Jan 1, 1993·Medical and Pediatric Oncology·M J Coppes
Aug 1, 1993·Fundamental and Applied Toxicology : Official Journal of the Society of Toxicology·T J FranzS D Gettings
Jul 23, 1996·Proceedings of the National Academy of Sciences of the United States of America·D LiuM S Sy
Sep 18, 1996·Journal of the National Cancer Institute·B S CroixR S Kerbel
Oct 11, 1996·Journal of Medicinal Chemistry·D J TaatjesT H Koch
Jan 1, 1997·British Journal of Cancer·K TamakoshiY Tomoda
Nov 14, 1997·International Journal of Cancer. Journal International Du Cancer·P BertrandB Delpech
Jan 22, 1998·The American Journal of Physiology·N S Chang
May 23, 1998·Annual Review of Immunology·J J Letterio, A B Roberts
Aug 26, 1998·Biochemical and Biophysical Research Communications·G B Carey, N S Chang
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·S M ZemanD M Crothers
Aug 24, 1999·Medical Oncology·W R FriedenbergJ K Burmester
Dec 3, 1999·Biochemical and Biophysical Research Communications·S Stair-NawyR Stern
Feb 9, 2000·Trends in Biochemical Sciences·P ten DijkeC H Heldin
Feb 9, 2000·Investigational New Drugs·W D Jarvis, S Grant
Oct 18, 2000·Critical Reviews in Oncology/hematology·B Desoize, J Jardillier

❮ Previous
Next ❯

Citations

May 30, 2008·Frontiers in Bioscience : a Journal and Virtual Library·Melanie A Simpson, Vinata B Lokeshwar
May 2, 2008·Seminars in Cancer Biology·Vinata B Lokeshwar, Marie G Selzer
Jan 7, 2003·The Journal of Biological Chemistry·Nan-Shan ChangAmy Ensign
Oct 2, 2007·Molecular and Cellular Biochemistry·Michael SliszDorothy Hutter
Dec 22, 2016·Frontiers in Cell and Developmental Biology·Li-Jin HsuNan-Shan Chang
Sep 6, 2005·Cancer Research·Vinata B LokeshwarBal L Lokeshwar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis